Promising results shown for kidney cancer drug
February 3, 2010 by admin · Leave a Comment
Contact: Ilene Rush
irush@shro.org
215-635-5162
Sbarro Health Research Organization
The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology.
FDA approves new drug for advanced kidney cancer
March 31, 2009 by admin · Leave a Comment
The U.S. Food and Drug Administration approved for sale a kidney-cancer drug that Novartis AG hopes to eventually expand to a variety of other cancers.
Discovery offers hope for treating kidney cancer
December 23, 2008 by admin · Leave a Comment
Kidney cancer is typically without symptoms until it has spread to other organs, when it is also the most difficult to treat. Newer chemotherapies show great promise for extending survival during later disease stages, but they can also be highly toxic.
Drug fends off kidney cancer progression
May 16, 2008 by admin · Leave a Comment
New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments. The study was led by Robert Motzer, MD, an attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), who will present the findings on May 31 at the annual meeting of the American Society for Clinical Oncology.
How less can be more when treating some kidney cancers
January 9, 2008 by admin · Leave a Comment
A new Mayo Clinic study suggests that removing the entire kidney from younger patients with small kidney tumors may lead to decreased overall survival compared with an operation that removes the tumor but leaves the kidney intact. The study will be published in the February issue of the Journal of Urology.
Experimental drug shows promise in advanced kidney cancer
September 26, 2007 by admin · Leave a Comment
Barcelona, Spain: A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.
The study, presented today (Wednesday) at the European Cancer Conference (ECCO 14) in Barcelona, showed that the experimental drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.
A Doctor and His Family, with 7 years of first-hand experience of life on dialysis
September 20, 2007 by admin · Leave a Comment
( Chicago ) According to the National Kidney Foundation, one out of every nine people in the United States is affected by kidney disease. DIALYSIS WITHOUT FEAR ( Oxford University Press, July 2007) is the first-ever family guide for dialysis patients who suffer from kidney/renal failure and who wish to simplify their lives and dispel the misconception that one must be “tied down” to their dialysis machine for the duration of their treatment, whether it be for a brief stint or for life.
What Is the Current Recommended Treatment for Lupus Nephritis?
Lupus nephritis is kidney disease that is caused by lupus. To start, it must be understood that there are many forms of kidney disease that are referred to as lupus nephritis. Each form is distinguished by characteristic patterns of abnormalities as defined by a kidney biopsy. (A biopsy is the removal of a sample of tissue for microscopic examination.) Typically, the findings on a kidney biopsy of a lupus patient are classified according to the appearance of the tissue and immune abnormalities seen under the microscope.
New Drug Combination Shrinks Kidney Cancers
May 31, 2006 by admin · Leave a Comment
DURHAM, N.C. — By using a new combination of two anticancer drugs, researchers at Duke University Medical Center have dramatically improved response rates of patients with metastatic kidney cancer, which is now generally considered incurable.
